Limitations of the Study
Although our study was a multi-center trial, it was limited by a
retrospective design and relatively small number of patients because
MA-PVCs are comparatively rare arrhythmias. The patients in this study
were also limited by having a high frequency of %PVCs (mean %PVC =
20.1 ± 8.6%) and disabling symptoms. Thus, the effect of the RFCA of
the MA-PVCs in patients with a low frequency of %PVCs and/or
asymptomatic patients was unfortunately unknown in this study. Moreover,
our study could not clarify the long term clinical benefit of RFCA of
MA-PVCs. Thus, whether our results can safely be extrapolated to the
inclusion of a larger number of patients, whether the use of contact
force catheters, and whether a longer follow-up period in these patients
is needed should be determined in further studies.